ערך בספרים למניה: ChromaDex Corp. (NAGE)

Chromadex Corp (NAGE) dominates the cellular metabolism segment thanks to robust intellectual property that prevents competitor dumping. The company's success is based on the protection of Tru Niagen rights, with margins standing at 1.05, while B2B contracts and DTC sales remain the key growth drivers. This daily price chart on GURU.Markets links these metrics to the brand's development vector within the longevity niche and the supply of NAD+ raw materials to global corporations.

Chromadex Corp (NAGE) focuses on biomedical research into cellular longevity and the creation of innovative nutraceuticals. The book value per share determines the portion of equity attributable to a single security upon full liquidation of the business. Analysis of the BVPS chart allows for an assessment of the real value of assets relative to market quotes. Growth in this indicator confirms the capitalization of R&D scientific potential. This metric characterizes the defensive qualities of the investment.